I-Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-26-8 Purity >99.0% (HPLC) I-Nintedanib Esylate Intermediate Factory

Incazelo emfushane:

Igama Lekhemikhali: Methyl 2-Oxoindoline-6-Carboxylate

CAS: 14192-26-8

Ubumsulwa: >99.0% (HPLC)

Ukubukeka: Impushana Ephuzi Okukhanyayo kuya Kunsundu

I-Intermediate ye-Nintedanib Esylate (CAS: 656247-18-6) ekwelapheni umdlavuza wamaphaphu ongewona omncane kanye ne-idiopathic pulmonary fibrosis (IPF)

Ikhwalithi Ephezulu, Ukukhiqizwa Kwezohwebo

E-Mail: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi oholayo nomphakeli we-Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) enekhwalithi ephezulu, ukukhiqizwa kwezentengiso.

Chemical Properties:

Igama Lekhemikhali	I-Methyl 2-Oxoindoline-6-Carboxylate
Omqondofana	2-Oxoindoline-6-Carboxylic Acid Methyl Ester;I-Methyl Oxindole-6-Carboxylate
Inombolo ye-CAS	14192-26-8
Inombolo yeCAT	I-RF-PI1524
Isimo Sesitoko	Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula	I-C10H9NO3
Isisindo samangqamuzana	191.19
I-Melting Point	184.0 ~ 190.0℃
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	Impushana Ephuzi Ekhanyayo ukuya Ensundu
1 H NMR Spectrum	Ihambisana Nesakhiwo
Ukuhlanzeka / Indlela Yokuhlaziya	>99.0% (HPLC)
Ukulahlekelwa Ekumisweni	<1.00%
Ukungcola Okuphelele	<1.00%
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	I-Intermediate ye-Nintedanib Esylate (CAS: 656247-18-6)

I-Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) Umzila Wokwenziwa

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.

Izinzuzo:

I-FAQ:

Isicelo:

I-Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) iyisisetshenziswa esimaphakathi esisetshenziselwa ukulungiselela i-Nintedanib Esylate (CAS: 656247-18-6).I-Nintedanib Esylate inamandla, i-oral triple angiokinase inhibitor eyakhiwe ngu-Boehringer Ingelheim eqondise izindlela ze-proangiogenic kanye ne-pro-fibrotic ezixhunyaniswa ne-vascular endothelial growth factor receptor, i-fibroblast growth factor receptor kanye nemindeni ye-plateletdered factor receptor, kanye ne-Src kanye ne-Flt-3. ama-kinases.I-Nintedanib Esylate igunyazelwe ukwelashwa kwe-idiopathic pulmonary fibrosis (IPF), isimo lapho amaphaphu eba nezibazi ngokuqhubekayo ngokuhamba kwesikhathi, yi-US FDA ngo-Okthoba 2014 kanye ne-EMA ngoJanuwari 2015. I-FDA yanikeza i-nintedanib esylate esheshayo , ukubuyekezwa okubalulekile, umkhiqizo wezintandane, nokuqokwa kwempumelelo.Iphinde yagunyazwa yi-EMA ngoNovemba 2014 ukuze yelashwe umdlavuza wamaphaphu weseli ongelona omncane ngokuhambisana ne-docetaxel ngemva kokwelashwa ngamakhemikhali komugqa wokuqala.